Skip to main content

Table 2 Baseline characteristics of smear-negative presumptive TB patients who received an Xpert® MTB/RIF by whether the clinician would have treated them without access to the Xpert result or not

From: Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert® MTB/RIF era: a cohort study

Characteristic

 

No pre-XP empirical diagnosis

Pre-XP empirical diagnosis

Missing response

Total

P-value

Total (n [%])

 

142

29

4

175

 

Age (mean[SD])

 

40 (11)

39 (9)

47 (11)

40 (11)

0.52

Female sex (n [%])

 

80 (56.3)

16 (55.2)

3 (75)

99 (56.6)

0.75

CD4 count (median [IQR])*

 

280 (189, 483)

238 (132, 343)

403 (390, 983)

275 (179, 478)

0.66

ART at TB treatment initiation (n [%])

 

72 (50.7)

16 (55.2)

1 (25)

89 (50.9)

0.53

Prior TB treatment (n [%])

 

23 (16.2)

6 (20.7)

0 (0)

29 (16.6)

0.55

Symptomatology at presentation (n [%])

Cough

140 (98.6)

29 (100)

4 (100)

173 (98.9)

0.79

Fever

101 (71.1)

19 (65.5)

4 (100)

124 (70.9)

0.36

Night sweats

72 (50.7)

13 (44.8)

3 (75)

88 (50.3)

0.51

Weight loss

48 (33.8)

14 (48.3)

1 (25)

63 (36)

0.3

Anorexia

67 (47.2)

14 (48.3)

3 (75)

84 (48)

0.55

Chest pain

46 (32.4)

10 (34.5)

1 (25)

57 (32.6)

0.93

  1. IQR interquartile range, n number, Rx treatment, SD standard deviation, TB tuberculosis, XP Xpert MTB/RIF
  2. *On 124, 26, 2 and 152 patients, respectively